{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:35:06Z","timestamp":1791282906911,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"National Library of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000179","name":"Office of the Director","doi-asserted-by":"publisher","award":["U01AI096299"],"award-info":[{"award-number":["U01AI096299"]}],"id":[{"id":"10.13039\/100000179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000179","name":"Office of the Director","doi-asserted-by":"publisher","award":["U01AI069911"],"award-info":[{"award-number":["U01AI069911"]}],"id":[{"id":"10.13039\/100000179","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Harmonist project","award":["R24AI124872"],"award-info":[{"award-number":["R24AI124872"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dolutegravir is being rolled out globally as part of preferred antiretroviral therapy (ART) regimens, including among treatment-experienced patients. The role of viral load (VL) testing before switching patients already on ART to a dolutegravir-containing regimen is less clear in real-world settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included patients from the International epidemiology Databases to Evaluate AIDS consortium who switched from a nevirapine- or efavirenz-containing regimen to one with dolutegravir. We used multivariable cause-specific hazards regression to estimate the association of the most recent VL test in the 12 months before switching with subsequent outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 36\u00a0393 patients at 37 sites in 5 countries (Democratic Republic of the Congo, Kenya, Rwanda, Tanzania, Uganda) who switched to dolutegravir from July 2017 through February 2020, with a median follow-up of approximately 11 months. Compared with those who switched with a VL &amp;lt;200 copies\/mL, patients without a recent VL test or with a preswitch VL \u22651000 copies\/mL had significantly increased hazards of an incident VL \u22651000 copies\/mL (adjusted hazard ratio [aHR], 2.89; 95% confidence interval [CI], 1.99\u20134.19 and aHR, 6.60; 95% CI, 4.36\u20139.99, respectively) and pulmonary tuberculosis or a World Health Organization clinical stage 4 event (aHR, 4.78; 95% CI, 2.77\u20138.24 and aHR, 13.97; 95% CI, 6.62\u201329.50, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A VL test before switching to dolutegravir may help identify patients who need additional clinical monitoring and\/or adherence support. Further surveillance of patients who switched to dolutegravir with an unknown or unsuppressed VL is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab1006","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T12:08:45Z","timestamp":1638619725000},"page":"630-637","source":"Crossref","is-referenced-by-count":23,"title":["Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa"],"prefix":"10.1093","volume":"75","author":[{"given":"Matthew L","family":"Romo","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics & Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, City University of New York , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie K","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggrey S","family":"Semeere","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Makerere University , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly S","family":"Musick","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Urassa","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research , Mwanza , Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Odhiambo","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute , Nairobi , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lameck","family":"Diero","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Health Sciences, Moi University , Eldoret , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kasozi","sequence":"additional","affiliation":[{"name":"Masaka Regional Referral Hospital , Masaka , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Murenzi","sequence":"additional","affiliation":[{"name":"Rwanda Military Hospital , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lelo","sequence":"additional","affiliation":[{"name":"Kalembelembe Pediatric Hospital , Kinshasa , Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wyka","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics & Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, City University of New York , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Kelvin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics & Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, City University of New York , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette H","family":"Sohn","sequence":"additional","affiliation":[{"name":"TREAT Asia, amfAR\u2013The Foundation for AIDS Research , Bangkok , Thailand and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara K","family":"Wools-Kaloustian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics & Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, City University of New York , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International epidemiology Databases to Evaluate AIDS (IeDEA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"2022120501032598500_CIT0001","author":"World Health Organization.","year":"2019"},{"key":"2022120501032598500_CIT0002","author":"World Health Organization.","year":"2021"},{"key":"2022120501032598500_CIT0003","author":"Clinton Health Access Initiative.","year":"2019"},{"key":"2022120501032598500_CIT0004","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"AIDS"},{"key":"2022120501032598500_CIT0005","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","article-title":"Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.","volume":"19","author":"Inzaule","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022120501032598500_CIT0006","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis.","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2022120501032598500_CIT0007","doi-asserted-by":"crossref","first-page":"e0164619","DOI":"10.1371\/journal.pone.0164619","article-title":"Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income countries: a forecast analysis 2015-2025.","volume":"11","author":"Gupta","year":"2016","journal-title":"PLoS One"},{"key":"2022120501032598500_CIT0008","doi-asserted-by":"crossref","first-page":"e035246","DOI":"10.1136\/bmjopen-2019-035246","article-title":"International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019.","volume":"10","author":"Chammartin","year":"2020","journal-title":"BMJ Open"},{"key":"2022120501032598500_CIT0009","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12879-016-1611-2","article-title":"Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm.","volume":"16","author":"Rutstein","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2022120501032598500_CIT0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.","volume":"16","author":"TenoRes Study Group.","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022120501032598500_CIT0011","author":"World Health Organization.","year":"2019"},{"key":"2022120501032598500_CIT0012","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/QAD.0000000000002470","article-title":"Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.","volume":"34","author":"Salou","year":"2020","journal-title":"AIDS"},{"key":"2022120501032598500_CIT0013","doi-asserted-by":"crossref","first-page":"dlab050","DOI":"10.1093\/jacamr\/dlab050","article-title":"High level of HIV drug resistance informs dolutegravir roll-out and optimized NRTI backbone strategy in Mozambique.","volume":"3","author":"Carnimeo","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2022120501032598500_CIT0014","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial.","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022120501032598500_CIT0015","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"2022120501032598500_CIT0016","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance.","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022120501032598500_CIT0017","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/ciw001","article-title":"Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges.","volume":"62","author":"Roberts","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022120501032598500_CIT0018","volume-title":"National AIDS Control Programme. National guidelines for the management of HIV and AIDS","author":"Ministry of Health, Community Development, Gender, Elderly, and Children (Tanzania).","year":"2019","edition":"7th ed"},{"key":"2022120501032598500_CIT0019","author":"National AIDS and STI Control Program (Kenya).","year":"2018"},{"key":"2022120501032598500_CIT0020","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(20)30211-3","article-title":"Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.","volume":"7","author":"Jewell","year":"2020","journal-title":"Lancet HIV"},{"key":"2022120501032598500_CIT0021","doi-asserted-by":"crossref","first-page":"19045","DOI":"10.7448\/IAS.17.1.19045","article-title":"Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.","volume":"17","author":"Duda","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2022120501032598500_CIT0022","doi-asserted-by":"crossref","first-page":"e1001111","DOI":"10.1371\/journal.pmed.1001111","article-title":"Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America.","volume":"8","author":"Chi","year":"2011","journal-title":"PLoS Med"},{"key":"2022120501032598500_CIT0023","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/QAI.0000000000000553","article-title":"Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008-2013.","volume":"69","author":"Fox","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022120501032598500_CIT0024","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/cid\/civ1004","article-title":"Retention in care and patient-reported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in eastern Africa: application of a sampling-based approach.","volume":"62","author":"Geng","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022120501032598500_CIT0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/inthealth\/ihz049","article-title":"Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study.","volume":"12","author":"Yonga","year":"2020","journal-title":"Int Health"},{"key":"2022120501032598500_CIT0026","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cix1140","article-title":"The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa.","volume":"66","author":"Osler","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022120501032598500_CIT0027","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"2022120501032598500_CIT0028","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1093\/cid\/cix1139","article-title":"Managing advanced HIV disease in a public health approach.","volume":"66","author":"Ford","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022120501032598500_CIT0029","doi-asserted-by":"crossref","first-page":"20798","DOI":"10.7448\/IAS.19.1.20798","article-title":"Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.","volume":"19","author":"Brooks","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2022120501032598500_CIT0030","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/tmi.12717","article-title":"Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.","volume":"21","author":"Ndahimana","year":"2016","journal-title":"Trop Med Int Health"},{"key":"2022120501032598500_CIT0031","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022120501032598500_CIT0032","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"2022120501032598500_CIT0033","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line in adults failing a tenofovir-based first-line regimen: a prospective cohort study.","volume":"35","author":"Keene","year":"2021","journal-title":"AIDS"},{"key":"2022120501032598500_CIT0034","article-title":"Prospective enhanced monitoring of dolutegravir-based first line in Malawi (oral abstract 35, session O-03).","author":"Temfack"},{"key":"2022120501032598500_CIT0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022120501032598500_CIT0036","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"key":"2022120501032598500_CIT0037","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"2022120501032598500_CIT0038","article-title":"Disparities in dolutegravir uptake affecting females of reproductive age with HIV in low- and middle-income countries following initial concerns about teratogenicity: an observational study.","author":"Romo","year":"2021","journal-title":"Ann Intern Med"},{"key":"2022120501032598500_CIT0039","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/QAD.0000000000002234","article-title":"Simplifying switch to second-line antiretroviral therapy in sub-Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.","volume":"33","author":"Shroufi","year":"2019","journal-title":"AIDS"},{"key":"2022120501032598500_CIT0040","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1093\/cid\/ciab086","article-title":"Participants on dolutegravir resuppress human immunodeficiency virus RNA after virologic failure: updated data from the ADVANCE trial.","volume":"73","author":"Pepperrell","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab1006\/42112133\/ciab1006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/4\/630\/45787052\/ciab1006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/4\/630\/45787052\/ciab1006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T01:03:49Z","timestamp":1670202229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/4\/630\/6453480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,5]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,5]]},"published-print":{"date-parts":[[2022,9,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab1006","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2021,12,5]]}}}